(Q57072034)

English

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

article

In more languages

Statements

scholarly article

0 references

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Peter A. Fasching

7

object named as

P A Fasching

0 references

11

object named as

H Brauch

0 references

author name string

T E Mürdter

1

0 references

W Schroth

2

0 references

L Bacchus-Gerybadze

3

0 references

S Winter

4

0 references

G Heinkele

5

0 references

W Simon

6

0 references

T Fehm

8

0 references

M Eichelbaum

9

0 references

M Schwab

10

0 references

language of work or name

0 references

publication date

30 March 2011

0 references

Clinical Pharmacology & Therapeutics

0 references

89

0 references

5

0 references

708-717

0 references

https://scigraph.springernature.com/pub.10.1038/clpt.2011.27

0 references

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Pharmacogenomics of tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

CYP2D6 and tamoxifen: DNA matters in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Drugs as CYP3A probes, inducers, and inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Coprescription of tamoxifen and medications that inhibit CYP2D6.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Aromatase inhibitors alone or in sequence with tamoxifen - clinical evaluation of the BIG 1-98 trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Rapid and Simple Method to Determine Tamoxifen and Its Major Metabolites in Human Liver Microsomes by High Performance Liquid Chromatography with Fluorescence Detection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

21 January 2018

Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.27

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2011.27

0 references

Dimensions Publication ID

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57072034&oldid=1962104553"